Inclusion criteria:

          -  Patients must have histologically or cytologically confirmed diagnosis (from primary
             lesion and/or lymph nodes) of Squamous Cell Cancer of the oropharynx, hypopharynx or
             larynx (For patients with oropharynx primary, the tumor must be negative for p16 by
             immunohistochemistry).

          -  Patients with selected Stage III or IV disease (T2 N2-3 M0, T3-4 any N M0, T1 N2b, N2c
             or N3p16 negative oropharynx cancer or T1-2 any N hypopharynx cancer) including no
             distant metastases.

          -  History/Physical examination by a Radiation Oncologist and Medical oncologist prior to
             entering the study.

          -  Examination by an ENT or Head & Neck Surgeon including laryngopharyngoscopy prior to
             entering the study.

          -  Patients must have a chest CT scan, or PET/CT scan to rule out metastatic disease

          -  Patients must have a contrast enhanced CT scan or MRI or PET/CT scan of the tumor site
             and neck nodes prior to entering the study.

          -  Patients must have an EKG and ECHO or MUGA scan prior to entering the study.

          -  Patients must have Zubrod Performance Status of 0-1.

          -  Patients must be ≥ 18 years of age.

          -  Patients must have normal organ and marrow function as defined below:

               -  Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3

               -  Platelets ≥ 100,000 cells/mm3

               -  Hemoglobin ≥ 8.0 g/dl

               -  Serum creatinine < 1.5 mg/dl or creatinine clearance (CC) ≥ 50 ml/min

               -  Total bilirubin < 2 x the institutional upper limit of normal

               -  AST or ALT ≤ 3 x the institutional upper limit of normal

          -  Patient must have magnesium, calcium, glucose, potassium and sodium levels within
             normal limits

          -  Women of childbearing potential must have a negative pregnancy test prior to
             registration.

          -  Patients of reproductive potential must practice effective contraception while on
             study and for at least 60 calendar days following treatment.

          -  All patients must sign an informed consent prior to enrollment.

          -  Patients must comply with the treatment plan and follow-up schedule.

        Exclusion criteria:

          -  Patients with simultaneous primaries or bilateral tumors.

          -  Patients who have had gross total excision of the primary tumor.

          -  Patients with initial surgical treatment, radical or modified neck dissection.

          -  Patients who received prior systemic chemotherapy for the study cancer.

          -  Patients who received prior radiotherapy to the region of the study cancer that would
             result in overlap of radiation therapy fields.

          -  Patients with primary tumor of oral cavity, nasopharynx, sinuses or salivary glands.

          -  Prior allergic reaction to the study drugs.

          -  Patients who have had prior therapy that specifically and directly targets the
             EGFR/HER2 pathway.

          -  Patients who have current active hepatic or biliary disease (with exception of
             patients with Gilbert's syndrome, asymptomatic gallstones, or stable chronic liver
             disease per investigator assessment);

          -  Pregnant women or sexually active patients not willing or able to use medically
             acceptable forms of contraceptive method while on treatment.

          -  Patients with severe, active co-morbidity, defined as follows:

               -  Uncontrolled cardiac disease, such as uncontrolled hypertension, unstable angina,
                  and/or congestive heart failure requiring hospitalization within the last 6
                  months

               -  Transmural myocardial infarction within the last 6 months

               -  Left ventricular ejection fraction < 45%

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time
                  of registration

               -  Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness
                  requiring hospitalization or precluding study therapy within 30 calendar days
                  prior to registration

               -  Hepatic insufficiency resulting in clinical jaundice and/or Coagulation defects

               -  Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition